Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672489 | 0.72 | CYP1A2 (0.62) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL6446470 | 0.70 | LMNA (0.44) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL23623700 | 0.69 | CYP1A2 (0.39) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL7120232 | 0.69 | CYP1A2 (0.58) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| Acrylic Acid SCHEMBL14576214 | 0.68 | KDM4E (0.49) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL30933403 | 0.67 | CYP1A2 (0.40) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL5238749 | 0.66 | MTNR1A (0.47) | KDM4E | |
| SCHEMBL9139507 | 0.66 | KDM4E (0.50) | CYP1A2KDM4EMEN1KMT2ALMNA | |
| SCHEMBL18090989 | 0.65 | CA1 (0.50) | KDM4ELMNA | |
| SCHEMBL7492321 | 0.64 | IRAK4 (0.62) | KDM4EMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745273-B2 | Phenazine derivatives as anti-neoplastic agents and anti-infective agents | UNIVERSITETET I OSLO (NO) | 2017-08-29 | — | — | US | disclosed |
| US-20160251320-A1 | Compounds | UNIVERSITÉ CLAUDE BERNARD LYON 1 (FR) | 2016-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251320-A1 | Compounds | NISCH, MDN1, PIR | CYP1A2 2834/4885KDM4E 4715/4885MEN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.